These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 16275499

  • 1. Circasemidian rather than circadian variation of circulating osteoprotegerin in clinical health.
    Tarquini R, Mazzoccoli G, Dolenti S, Gaudiano P, Comuni C, Laffi G, Perfetto F, Otsuka K, Cornélissen G, Halberg F.
    Biomed Pharmacother; 2005 Oct; 59 Suppl 1(Suppl 1):S225-8. PubMed ID: 16275499
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I, Balon BP, Rus I, Marc J.
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [Abstract] [Full Text] [Related]

  • 4. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E, González-Reimers E, Santolaria-Fernández F, De la Vega-Prieto MJ, Milena-Abril A, Sánchez-Pérez MJ, Martínez-Riera A, Gómez-Rodríguez Mde L.
    Alcohol Alcohol; 2006 Mar; 41(3):261-6. PubMed ID: 16476762
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The circadian rhythm of osteoprotegerin and its association with parathyroid hormone secretion.
    Joseph F, Chan BY, Durham BH, Ahmad AM, Vinjamuri S, Gallagher JA, Vora JP, Fraser WD.
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3230-8. PubMed ID: 17550963
    [Abstract] [Full Text] [Related]

  • 7. Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients.
    Grzegorzewska AE, Mlot M.
    Adv Perit Dial; 2005 Aug; 21():188-93. PubMed ID: 16686316
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients.
    Malyszko J, Malyszko JS, Wolczynski S, Mysliwiec M.
    Transplant Proc; 2003 Sep; 35(6):2227-9. PubMed ID: 14529897
    [Abstract] [Full Text] [Related]

  • 10. Increased levels of osteoprotegerin in hemodialysis patients.
    Avbersek-Luznik I, Malesic I, Rus I, Marc J.
    Clin Chem Lab Med; 2002 Oct; 40(10):1019-23. PubMed ID: 12476941
    [Abstract] [Full Text] [Related]

  • 11. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction.
    Geusens PP, Landewé RB, Garnero P, Chen D, Dunstan CR, Lems WF, Stinissen P, van der Heijde DM, van der Linden S, Boers M.
    Arthritis Rheum; 2006 Jun; 54(6):1772-7. PubMed ID: 16736519
    [Abstract] [Full Text] [Related]

  • 12. Osteoprotegerin and bone mineral density in hemodiafiltration patients.
    Crisafulli A, Romeo A, Floccari F, Aloisi E, Atteritano M, Cincotta M, Aloisi C, Pizzoleo MA, Ruello A, Artemisia A, Valenti A, Frisina N, Teti D, Buemi M.
    Ren Fail; 2005 Jun; 27(5):531-9. PubMed ID: 16152990
    [Abstract] [Full Text] [Related]

  • 13. Serum osteoprotegerin and renal osteodystrophy.
    Coen G, Ballanti P, Balducci A, Calabria S, Fischer MS, Jankovic L, Manni M, Morosetti M, Moscaritolo E, Sardella D, Bonucci E.
    Nephrol Dial Transplant; 2002 Feb; 17(2):233-8. PubMed ID: 11812872
    [Abstract] [Full Text] [Related]

  • 14. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
    Fábrega E, Orive A, García-Suarez C, García-Unzueta M, Antonio Amado J, Pons-Romero F.
    Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
    [Abstract] [Full Text] [Related]

  • 15. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
    Abrahamsen B, Hjelmborg JV, Kostenuik P, Stilgren LS, Kyvik K, Adamu S, Brixen K, Langdahl BL.
    Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
    [Abstract] [Full Text] [Related]

  • 16. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.
    Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R.
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4470-5. PubMed ID: 12364420
    [Abstract] [Full Text] [Related]

  • 17. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status.
    Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3162-5. PubMed ID: 11443182
    [Abstract] [Full Text] [Related]

  • 18. Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples.
    Seck T, Diel I, Bismar H, Ziegler R, Pfeilschifter J.
    Eur J Endocrinol; 2001 Aug; 145(2):199-205. PubMed ID: 11454517
    [Abstract] [Full Text] [Related]

  • 19. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
    Kondo H, Guo J, Bringhurst FR.
    J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
    [Abstract] [Full Text] [Related]

  • 20. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men.
    Khosla S, Atkinson EJ, Dunstan CR, O'Fallon WM.
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1550-4. PubMed ID: 11932280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.